1:19   礼来（Eli Lilly）拟以最高38亿美元收购Atai Beckley，这一动作不仅是单纯的并购案，更是精神病治疗领域的一个里程碑式转折点，标志着迷幻疗法正式从“边缘科学”迈入“主流医学”殿堂。 1:55   Lilly Buys Psychedelic Drugmaker AtaiBeckley for $3.8 Billion 3:21   Lilly to Buy Psychedelic Firm AtaiBeckley for Up to $3.8 Billion 5:27   礼来收购 AtaiBeckley：38亿美元买的不只是迷幻药Why is Eli Lilly willing to pay up to $3.8 billion for AtaiBeckley? 8:00   Atai Life Sciences Acquisition: My Take on the 8-K 8:44   Psilocybin Just Held Up at Six Months. Big Pharma Bought the Competitor. 5:08   Eli Lilly's $3.8 Billion Bet On Magic Mushrooms & LSD: What It Means For Mental Healthcare | N18S 10:14   My prediction for Psychedelic Medicines | Christian Angermayer | Atai Life Sciences | MindMed 11:30   ATAI Life Sciences' Plan to Boost Shareholder Value and Field Trip's Fight Against Bankruptcy 4:33   Netflix Drops, AtaiBeckley Jumps, Abbott Surges | Stock Movers 0:41   Atai: Psychedelic mushroom startup studying depression